View Older Stories View More Recent Stories

Nov 19, 2015 06:30AM Lilly and Merck Expand Immuno-oncology Collaboration with Phase III Nonsquamous Non-Small Cell Lung Cancer Trial
Nov 17, 2015 08:00AM New Studies Investigating the Use of KEYTRUDA® (pembrolizumab) Across Solid and Hematological Cancers to Be Presented at Upcoming Congresses
Nov 16, 2015 08:30AM Merck Announces Presentation of Results from Two Phase 2 Studies of Investigational Triple-Combination Chronic Hepatitis C Therapy at The Liver Meeting®
Nov 14, 2015 07:00PM Merck Announces Presentation of Phase 3 Results of Investigational Elbasvir/Grazoprevir in People with Chronic Hepatitis C Genotypes 1, 4 or 6 Infection Who Inject Drugs and Are on Opioid Agonist Ther
Nov 14, 2015 07:00PM Merck to Release Findings from Integrated Analysis of Six Phase 2 and 3 Clinical Trials Evaluating Investigational Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1, 4 or 6 Infectio
Nov 13, 2015 08:00AM Merck Provides Update on REVEAL Outcomes Study
Nov 12, 2015 05:00PM Merck Animal Health to Acquire Harrisvaccines
Nov 12, 2015 11:49AM Merck Statement Regarding CUBICIN® (daptomycin for injection) Patent Litigation
Nov 6, 2015 02:13PM Merck Statement on FDA Advisory Committee Meeting for BRIDION® (sugammadex), Investigational Agent for the Reversal of Neuromuscular Blockade (NMB) Induced by Rocuronium or Vecuronium
Nov 6, 2015 09:31AM Data on Vericiguat, Investigational Heart Failure Medicine, to be Presented as Late-Breaking Clinical Trial at the 2015 American Heart Association (AHA) Scientific Sessions
Nov 5, 2015 08:43AM Merck Announces Samsung Bioepis Will Present New Biosimilars Data at the 2015 ACR/ARHP Annual Meeting
Nov 3, 2015 06:58AM GSK and Merck to Study Immunotherapy Combination as Potential Cancer Treatment
Nov 2, 2015 08:00AM Merck Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for KEYTRUDA® (pembrolizumab) in Advanced Colorectal Cancer
Oct 28, 2015 08:00AM KEYTRUDA® (pembrolizumab) from Merck Awarded Prix Galien USA 2015 Best Biotechnology Product Award
Oct 27, 2015 05:36PM Market Wrap: Suprise Dip in Confidence for Oct.; Apple Gains on iPhone Sales; Walgreens Boots Moves to Acquire Peer
Oct 27, 2015 07:15AM Wall St. slips on rate uncertainty; Apple up after the bell
Oct 27, 2015 06:45AM Merck Announces Third-Quarter 2015 Financial Results
Oct 26, 2015 02:16PM Trading Radar for 10/26: Apple (AAPL), Twitter (TWTR), Alibaba (BABA), Comcast (CMCSA), Pfizer (PFE) Report
Oct 26, 2015 09:00AM Merck’s KEYTRUDA® (pembrolizumab) Shows Superior Overall Survival Compared to Chemotherapy in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer Whose Tumors Express PD-L1
Oct 26, 2015 08:00AM Merck and the National Sleep Foundation Urge Insomnia Sufferers to Prioritize Sleep and Move Beyond Tired
Oct 20, 2015 10:35AM Merck to Present New Data on Investigational Chronic Hepatitis C Treatment Elbasvir/Grazoprevir at The Liver Meeting® 2015, Including Phase 3 Results in Selected Difficult-to-Treat Populations
Oct 16, 2015 02:58PM Celebrity Chef Leticia Moreinos Schwartz, Merck and the American Diabetes Association Challenge Hispanics with Type 2 Diabetes to Get to Their A1C Goal
Oct 14, 2015 09:05AM Market’s Only Cancer Immunotherapy ETF Launches
Oct 13, 2015 07:30AM Incyte and Merck Expand Clinical Collaboration to Include Phase 3 Study Investigating the Combination of Epacadostat with Keytruda® (pembrolizumab) as First-line Treatment for Advanced Melanoma
Oct 9, 2015 08:00AM Award-Winning Actress S. Epatha Merkerson, Merck and the American Diabetes Association Challenge African Americans with Type 2 Diabetes to Get to Their A1C Goal
Oct 9, 2015 07:00AM KEYTRUDA® (pembrolizumab) Receives New Draft Recommendation from National Institute for Health and Care Excellence (NICE) in U.K. for First-Line Treatment for Advanced Melanoma
Oct 5, 2015 07:01PM Results from Merck’s Phase 3 Study of Investigational Chronic Hepatitis C Therapy Elbasvir/Grazoprevir in Patients with Advanced Chronic Kidney Disease Published in The Lancet
Oct 5, 2015 05:15PM Merck Congratulates Awardees of 2015 Nobel Prize in Physiology or Medicine for Discovery Leading to River Blindness Treatment
Oct 2, 2015 02:49PM FDA Approves KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 with Disease Progression On or After Platinum-Containing Che
Oct 1, 2015 08:00AM Merck and DNAtrix Announce Phase 2 Immuno-Oncology Collaboration in Patients with Aggressive Form of Brain Cancer
Sep 29, 2015 10:30AM International Coalition Urges Final Push to Eliminate River Blindness from the Americas
Sep 29, 2015 08:10AM EMD Serono Joins Industry Leaders for The Economist Events' War On Cancer Forum in Boston
Sep 28, 2015 08:00AM Syndax And Merck Announce First Patients Dosed In Phase 1b/2 Clinical Trial Of Entinostat And KEYTRUDA®
Sep 28, 2015 07:30AM MARIZEV® (Omarigliptin), Merck’s Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes, Approved in Japan
Sep 27, 2015 07:00AM New Data from KEYNOTE-028, Merck’s Trial Evaluating KEYTRUDA® (pembrolizumab) Across a Range of Cancer Types, Presented at 2015 European Cancer Congress
Sep 26, 2015 07:00AM New Findings Show Anti-Tumor Activity of KEYTRUDA® (pembrolizumab) in Patients with Advanced Nasopharyngeal Carcinoma
Sep 25, 2015 08:00AM Merck to Hold Third-Quarter 2015 Sales and Earnings Conference Call on October 27
Sep 21, 2015 08:00AM Data in Nine Difficult-to-Treat Cancers from Merck’s KEYTRUDA® (pembrolizumab) Development Program to be Presented at European Cancer Congress 2015, Including Data in Four New Cancer Types: ...
Sep 20, 2015 12:30PM Pivotal Phase 3 Studies of Bezlotoxumab, Merck’s Investigational Antitoxin to Prevent Clostridium Difficile Infection Recurrence, Met Primary Endpoint
Sep 18, 2015 03:00PM Results of Phase 2 Study of Merck’s Investigational Beta-Lactamase Inhibitor Relebactam Presented at ICAAC/ICC 2015
Sep 17, 2015 08:30AM Merck Provides Diabetes Portfolio Update and Underscores Comprehensive, Long-Term Commitment to Patients with Diabetes
Sep 16, 2015 10:16AM Merck’s Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor, Achieved Similar A1C Reductions to JANUVIA® (sitagliptin) in Patients with Type 2 Diabetes Inadequately Controlled on Metformin
Sep 16, 2015 08:00AM Merck to Participate at the Morgan Stanley Global Healthcare Conference
Sep 16, 2015 07:30AM Merck Highlights Its Commitment to Infectious Disease with 40 Presentations of Data at ICAAC/ICC 2015
Sep 10, 2015 09:00AM Merck Publishes 2014 Global Corporate Responsibility Report
Sep 8, 2015 08:30AM Merck and Samsung Bioepis Announce Approval of BRENZYS™ (Etanercept), a Biosimilar of Enbrel, in Korea
Sep 2, 2015 08:00AM FDA Approves Pediatric Indication for EMEND® (aprepitant) Capsules in Combination with Other Antiemetic Agents
Sep 1, 2015 09:00AM New Analyses from the IMPROVE-IT Study with VYTORIN® (ezetimibe and simvastatin)
Aug 20, 2015 08:30AM New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® (sitagliptin) Will Be Presented at the European Society
Aug 18, 2015 01:17PM Merck Recalls TEMODAR® and Temozolomide Bottles with Cracked Caps Due to Failure to Meet Child–Resistant Closure Requirement
View More Recent Stories View Older Stories